Members of the US Public Health Service Task Force have suggested that prophylaxis for Pneumocystis carinii pneumonia could be considered in HIV-infected patients with CD4 counts greater than 200/mm3. Current recommendations state that prophylaxis should begin when CD4 levels fall below 200/mm3. However, estimates from the US Centers for Disease Control say that 6% of patients have their first PCP episode when CD4 counts are between 200 and 300/mm3, translating to a prevention of 373 cases at current patient levels.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze